Analyse. GENTA Kursexplosionsgefahr!!

die 0,062 sind genommen in USA  

 

 

 

Starke Käufe  

 

American Society of Clinical  Oncology (ASCO)

Freitag, 4. Juni 2010 to   Dienstag, 8. Juni 2010

Chicago, IL

das sind jetzt wohl nur die vorboten. wenn ray waat positives von sich gibt, werden wir alt bekannte kurse erleben. und wehe tesetaxel ist in phase IIb erfolgreich und geht in phase III über. nicht auszudenken wir hören nochmals gute news über genasense. OH OH!!!

http://de.advfn.com/...NTA&p=0&t=16&dm=0&vol=1&cb  

und hoffe auf schnelle Gewinne, normal hab ich bei sowas kein Glück :)  

Geh wieder raus. Seit du drin bist gehts runter

Aber noch ist nicht Abpfiff.  

ich bin schon ganz kribelig... schaut euch mal den 3 monats chart an... genta nimmt einen riesen anlauf richtig abzugehen... 

hoffentlich sehen wir bald wieder 0.5EUR.. w#re der HAMMMA..Also allen investieren viel glück und erfolg :)

 

Chart sieht einladend aus, das zieht morgen bestimmt die Zocker wieder an und dann gehts hier ab. Außerdem will ich auch kein Buhmann sein ;)  

naaaa, wie erwartet ging es gestern schon langsam Bergauf, habe erst heute damit gerechnet aber wollen mal nicht meckern ;-).

Meiner Meinung nach ist ein weiterer Anstieg so sicher wie das Amen in der Kirche. Ganz logisch, Ray teilt uns am WE mit wie Stand der Dinge ist und da will natürlich jeder dabei sein.

Ich habe verpasst nochmal nachzukaufen aber meine mom Stückzahl reicht bei einem weitern Höhenflug für nen kleinen Urlaub, mehr will ich ja garnicht ;-)

Auf eine super grüne Wochenendphase...  

Ich sehe auch einen weiteren Anstieg heute  

 

http://niceinterestingcharts.blogspot.com/2010/06/...ing-for-20s.html  

mensch dubist aber bescheiden... :)
 

Wenn ich immer nach einem Cent Anstieg höre wieviel Millionäre geboren sind, bleib ich doch einfach aufn Teppich :-) lieber ehrlich und bescheiden als rumprahlen und im endefekt mehr verloren als man zugeben mag  

Genta Incorporated Announces Webcast of 2010 Annual Shareholders Meeting
Datum : 11/06/2010 @ 14h10
Quelle : Business Wire
Name : Genta Incorporated (GETA)
Kurs :  0.0429  0.0 (0.00%) @ 13h50


Genta Incorporated Announces Webcast of 2010 Annual Shareholders Meeting
Genta Incorporated (OTCBB: GETA.OB) announced that the Company will host a conference call and live audio webcast of its 2010 Annual Meeting of Shareholders. The meeting will be held on Tuesday, June 15, 2010 at 9:00 am ET at The Madison Hotel in Morristown, NJ. Company management will present an overview of the Company’s research programs, clinical and regulatory strategies, and timelines.

Conference Call and Webcast Information:

Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html.

For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is: 77021779. Shareholders wishing to attend the meeting may call the hotel at 1-800-526-0729 for directions.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genasense® is being developed as an agent that may enhance the effectiveness of anticancer therapy. The Company is currently collecting long-term followup data on durable response and overall survival from the recently completed randomized Phase 3 study of Genasense® in patients with advanced melanoma (the AGENDA trial). The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Genta has initiated a broad clinical program to evaluate the safety and efficacy of tesetaxel in patients with solid tumors. In the U.S., Genta is exclusively marketing Ganite® (gallium nitrate injection), which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite® that are being evaluated as potential treatments for diseases associated with accelerated bone loss. Ganite® and Genasense® are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words “potentially”, “anticipate”, “could”, “calls for”, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:

the Company’s ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency;
the safety and efficacy of the Company’s products or product candidates;
the commencement and completion of any clinical trials;
the Company’s assessment of its clinical trials;
the Company’s ability to develop, manufacture, license, or sell its products or product candidates;
the Company’s ability to enter into and successfully execute any license and collaborative agreements;
the adequacy of the Company’s capital resources and cash flow projections, or the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations;
the adequacy of the Company’s patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2009 and its most recent quarterly report on Form 10-Q.






http://ih.advfn.com/...mona&article=43195190&symbol=NB%5EGETA  

Genta Incorporated Reports Second Quarter 2010 Corporate Highlights and Financial Results

http://www.finanznachrichten.de/...ghts-and-financial-results-004.htm

Die Zahlen sehen doch gar nicht so schlecht aus!

Gruß
Ernie0815

de.advfn.com/p.php